Elevated levels of neurofilament light chain (Nfl) in CSF and plasma are one promising biomarker for symptomatic FTD patients that harbor mutations in GRN, C9orf72, or MAPT [118]. This evidence concerns the gene C9orf72 and frontotemporal dementia.